Iovance’s $211M offering; Almirall licenses Novo drug; AstraZeneca files Dato-DXd; Sonata layoffs

Plus other news you may have missed from the FTC, Everest, Gilead, IsomAb, Oramed, Innovent, Sonata, Larimar and Immunome.

Iovance Biotherapeutics offers $211M in shares: The company is selling more than 23 million shares for $9.15 each with the offering expected to close on February 22. The cash should support the launch of Iovance’s T cell therapy Amtagvi, which was approved Friday, and late-stage studies of its pipeline drugs. — Ayisha Sharma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Study highlights delays in care for pediatric trauma patients

Severely injured children who are brought to an emergency medical department by their parents or carers are often not seen as quickly as those who

October 14, 2024

Device made by company J&J is buying for $13 billion clears hurdle in independent study

A fully independent clinical trial researchers thought might disprove a cardiac device made by Shockwave Medical, the company that Johnson & Johnson is buying for

April 8, 2024

Bayer set to expand Kerendia’s label in cardiology with Phase III win

Bayer’s Kerendia is approved by the FDA for reducing cardiovascular risks and kidney function decline in adult patients with chronic kidney disease associated with type

August 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.